🔗 Share this article

As the US undertakes historic revisions to its vaccine schedules, an unexpected name appears in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent physician and public health researcher who first made her name by expressing skepticism about COVID-19 vaccines in the pandemic and has concentrated on possible deaths following Covid immunization in her recent position at the US Food and Drug Administration (FDA).

Planned Changes to Pediatric Immunization Schedule

Public health authorities had intended to reveal radical changes to the childhood vaccination calendar recently, aligning the US with the Danish immunization schedule, according to reports – a substantial departure that would put the US out of step with a large portion of the world with no evidence for benefit. This reveal has been pushed back until the coming year.

Instead of Vinay Prasad, Høeg is set to present at the meeting. She was just designated interim head of the FDA’s CDER, the fifth person to run the division this year.

A Shift at the Agency

This interim role may indicate a closer partnership between the drug and biologics centers as Dr. Høeg and Prasad consolidate power at the agency – and it points to a renewed priority upon dismantling previously authorized immunizations at the FDA.

Dr. Høeg has frequently advocated for discontinuing some pediatric shot schedules in the US so as to align more similar to the Danish model, a country with comprehensive healthcare and a citizenry roughly the size of the state of Wisconsin.

In her initial statements, she has persisted in emphasizing on immunizations – traditionally the purview of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Doubts Over Background

Dr. Høeg has no obvious experience in medication creation, approval processes or leadership, which has been typical for previous leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the agency head and CBER since March.

“It seems she lacks to have the requisite experience” for leading the pharmaceutical oversight division, remarked Jonathan Howard. “She’s never run a scientific study. She has no expertise in leading a large organization. She has no expertise in drug approvals.”

Past heads of the center would “grasp regulatory frameworks and the science of drug development”, noted a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that former directors who led the center have had.”

This division has an enormous workload at the agency, the former commissioner pointed out.

“Everybody just focuses on the new drug program, but the generic program authorizes thousands of off-brand pharmaceuticals. There is also a biosimilars program, OTC medication office and so forth, and all of those need to be managed,” she said. “The area you overlook, that is the part that I always told people is going to cause problems.”

There is also, a major administrative element to the position, which supervises more than 5,000 personnel. “It is a massive leadership role, if you perform it correctly,” the former official concluded.

Official Statement and Contentious Policies

In response to questions about Dr. Høeg's qualifications and whether this assignment signifies increased cooperation among agency officials on immunizations, a press secretary said that the “questions are based on flawed assumptions”.

“Her resume is consistent with the functions of her position,” the official said, noting the period Høeg spent counseling the FDA commissioner on “medication safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Høeg takes over the commissioner’s new priority voucher program, a contentious rapid therapy clearance system that allegedly troubled her predecessors. “How are these drugs being selected for this expedited pathway? Who makes the choices?” Howard questioned. “There is a lot of lack of transparency occurring at the regulatory body right now.”

Overall, he remarked, “the agency appears to be shifting towards laxer oversight of most medications, with the exception of vaccines.”

Documented Past Work on Immunizations

With immunizations, Dr. Høeg has a more established, if troubling, history, Howard observe. She published a study using unverified crowd-sourced reports to determine the incidence of heart inflammation after Covid vaccination. She counseled the Florida chief medical officer Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccinations are pose a greater threat than they are.

Among her “policy goals” for the new federal leadership featured changing regulations for recently developed shots and ending “unnecessary” immunizations, she stated post-election on a audio program. At the agency, Høeg has according to sources suggested preventing adolescent males from getting COVID-19 vaccinations.

“She is an thorough dogmatist who commences with her preconceived notions and works backwards to fit the data in a highly misleading, dishonest way,” Howard stated.

Taking Control and a “Push for Payback”

Høeg became part of other contrarians, {like|